Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Alpha Source Group
Allan Klotsche, former CEO of National Business Furniture, has been named CEO of Alpha Source Group. Klotsche served as a member of Alpha’s board from 2015 until July 2020.
Ascentage Pharma has tapped Gang Zhu as the company’s new chief commercial officer. Previously, Zhu served as general manager of Celgene China.
Avadel Pharmaceuticals has named Jennifer Gudeman vice president of medical and clinical affairs. Gudeman previously served as vice president of medical affairs at AMAG Pharmaceuticals.
Kathy McGee has assumed the role of chief operating officer at AVITA Therapeutics. Formerly, McGee served as president of CnA Consulting Group.
C4X Discovery Holdings
Clive Dix, CEO of C4XD, has assumed the role of interim CEO of the UK Vaccine Task Force, where he will lead the development of a COVID-19 vaccine.
Rebecca Bagley has been named CEO of Cannex Scientific. Prior to this appointment, Bagley served as vice chancellor for economic partnerships at the University of Pittsburgh.
Cellares has named Einav Kraft the company’s new vice president of quality. Most recently, Kraft was the site head of quality for Miltenyi Biotec.
Chiesi USA has appointed Jon Zwinski to be general manager and CEO of the company. Zwinski was most recently the senior vice president of sales and head of the cardiovascular business unit at Chiesi.
Congenica has hired Muthu Meyyappan as the company’s new chief commercial officer. Meyyappan was previously the chief commercial officer at Variantyx.
Antony Blanc has assumed the roles of chief business officer and chief commercial officer of CureVac. Blanc’s previous role included vice president and global integration lead for GlaxoSmithKline’s vaccines unit.
Kara Carter has been named senior vice president of discovery biology at Dewpoint Therapeutics. Carter joins Dewpoint from Evotec, where she served as executive vice president of infectious diseases.
Tara Kieffer has been appointed senior vice president of new product strategy and development at Enanta Pharmaceuticals. Kieffer previously served as vice president of external innovation and business development at Vertex Pharmaceuticals.
Entrada Therapeutics has appointed Nerissa Kreher to the role of chief medical officer. Formerly, Kreher was global head of clinical and medical affairs at Zafgen. Also, Kory Wentworth has been named chief financial officer of Entrada. Wentworth was previously the vice president and principal accounting officer at bluebird bio.
Ascletis subsidiary Gannex has signed on Melissa Palmer as its new chief medical officer. In her previous role at Takeda, Palmer led the company’s liver disease clinical development.
Global Blood Therapeutics
Global Blood Therapeutics has hired Kim Smith-Whitley, formerly the clinical director of hematology and director of the Comprehensive Sickle Cell Center at Children’s Hospital of Philadelphia, to lead Global Blood’s R&D programs.
Kronos Bio has named Pasit Phiasivongsa senior vice president of pharmaceutical development. Recently, Phiasivongsa served as senior vice president of technical operations at Sanofi’s Principia Biopharma.
Marizyme has hired Steven Brooks, former interventional cardiologist at the University of Maryland Medical Center, as the company’s new executive vice president of medical and regulatory affairs and its chief medical officer. Donald Very has also been brought on as Marizyme’s new executive vice president of R&D. Very was most recently senior vice president of Mosaigen.
Anne Brindley has been appointed CEO of drug repurposing specialist company Nuformix. Previously, Brindley served as CEO of Advent Pharmaceuticals.
Steve Harbin has been named chief operating officer and chief of staff of Oncorus. Before he joined Oncorus, Harbin served as a consultant to several early-stage biotech companies in the Boston area.
Oyster Point Pharma
Oyster Point Pharma has appointed Marian Macsai to the role of chief medical officer and Eric Carlson to the role of chief scientific officer. Macsai most recently served as chief of the division of ophthalmology for NorthShore University Health System, and Carlson was previously the chief scientific officer and executive vice president at Akorn Pharmaceuticals.
Pipeline Therapeutics has named Julie Iwashita the company’s vice president of clinical operations. Iwashita comes to Pipeline after most recently serving in the same role at Cirius Therapeutics.
Protara Therapeutics has promoted Jacqueline Zummo, the company’s co-founder and senior vice president of research and development operations, to the role of chief scientific operations officer.
Amy Broidrick has been named executive vice president and chief strategy officer of Qualigen Therapeutics. Broidrick was most recently the senior vice president and head of corporate development at Viking Therapeutics.
Formerly executive vice president of Samsung Biologics, John Rim has been appointed president and CEO of the company.
Michiel Van Speybroeck has been hired as SeraNovo’s new chief development officer. Van Speybroeck’s most recent role was as the corporate technology officer at Ardena.
Gary Fortin, former head of business strategy and operations at bluebird bio, has been appointed chief operating officer of Shape Therapeutics.
Ophthalmic company SIFI has appointed Jelle Kleijn to the role of global head of acanthamoeba keratitis. Kleijn was most recently the medical affairs lead in oncology and hematology for Amgen.
Sumitra Pillai has been appointed head of R&D at Slayback Pharma. Most recently, Pillai was vice president of R&D at Dr. Reddy’s Laboratories.